var data={"title":"Juvenile polyposis syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Juvenile polyposis syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributors\" class=\"contributor contributor_credentials\">Daniel C Chung, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributors\" class=\"contributor contributor_credentials\">Tomer Adar, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributors\" class=\"contributor contributor_credentials\">J Thomas Lamont, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributors\" class=\"contributor contributor_credentials\">Barbara Goff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributors\" class=\"contributor contributor_credentials\">Shilpa Grover, MD, MPH, AGAF</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Nov 13, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H620603917\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Juvenile polyposis syndrome (JPS) is an autosomal dominant condition characterized by multiple hamartomatous polyps throughout the gastrointestinal tract. Individuals with JPS are at increased risk for colorectal and gastric cancer [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In contrast to JPS, sporadic juvenile polyps of the colon occur in up to 2 percent of children under the age of 10 years, are usually solitary, and are not associated with an increased cancer risk [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>This topic will review the clinical manifestations, diagnosis, and management of JPS. The clinical manifestations and diagnosis of other hamartomatous polyposis syndromes (eg, Peutz-Jeghers syndrome, Cowden syndrome, and Bannayan-Riley-Ruvalcaba syndrome) and adenomatous polyposis syndromes (eg, familial adenomatous polyposis and <em>MUTYH</em>-associated polyposis) are discussed in detail, separately [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of familial adenomatous polyposis&quot;</a> and <a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">&quot;MUTYH-associated polyposis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H369224197\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JPS is rare, with an estimated incidence of 1 in 100,000 to 160,000 individuals [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H369224190\"><span class=\"h1\">GENETICS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JPS is an autosomal dominant condition with incomplete penetrance [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. JPS occurs as a result of germline mutations in the <em>SMAD4 </em>(<em>MADH4</em>) or bone morphogenetic protein receptor type-1A (<em>BMPR1A</em>)<em> </em>genes, which are related to the transforming growth factor-beta (TGF-beta) signaling pathway [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/6,7\" class=\"abstract_t\">6,7</a>]. Mutations in <em>SMAD4</em> or <em>BMPR1A</em> are identified in approximately 60 percent of JPS patients. Approximately 25 percent of patients have de novo mutations [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/8,9\" class=\"abstract_t\">8,9</a>]. </p><p>The <em>SMAD4 </em>gene is located on chromosome 18q21.1 and encodes for a cytoplasmic mediator of the TGF-beta signaling pathway. <em>SMAD4</em> forms heteromeric complexes with other proteins of the <em>SMAD</em> family, and these complexes then act within the nucleus [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/5,10\" class=\"abstract_t\">5,10</a>].</p><p>The <em>BMPR1A</em> (<em>ALK3</em>) gene is located on chromosome 10q22-23 and encodes a <span class=\"nowrap\">serine/threonine</span> kinase receptor protein that is also involved in the TGF-beta signaling pathway. Upon activation, <em>BMPR1A</em> phosphorylates <em>SMAD</em> family proteins [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/5\" class=\"abstract_t\">5</a>]<em>.</em> Individuals with <em>SMAD4</em> mutations may have more profuse polyposis of the upper gastrointestinal tract and a higher risk of cancer as compared with individuals with a <em>BMPR1A </em>mutation [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/11\" class=\"abstract_t\">11</a>]. </p><p>An association between JPS due to <em>SMAD4</em> mutations and hereditary hemorrhagic telangiectasia (HHT) has also been described [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. <em>SMAD4</em>-positive JPS patients frequently have clinical manifestations of HHT [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/13\" class=\"abstract_t\">13</a>]. There are case reports of germline mutations in the <em>ENG</em> gene that result in HHT in patients with JPS [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/14\" class=\"abstract_t\">14</a>]. The <em>ENG</em> gene, located on chromosome 9q34.1, encodes for the protein endoglin, which is an accessory protein of TGF-beta signaling. However, there are insufficient data to suggest that a mutation in the <em>ENG</em> gene predisposes to JPS [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/15\" class=\"abstract_t\">15</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H6\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Disease-causing DNA sequence variants in HHT'</a>.)</p><p class=\"headingAnchor\" id=\"H369224170\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H620604182\"><span class=\"h2\">Gastrointestinal manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Polyps usually begin to appear in the first decade of life, and patients can develop between five to hundreds of polyps in their lifetime. Polyps occur predominantly in the colorectum (98 percent) but can occur in the stomach (14 percent), duodenum (7 percent), jejunum, and ileum (7 percent). Generalized juvenile polyposis refers to polyps in the upper and lower gastrointestinal tract, and juvenile polyposis coli refers to polyps of the colon and rectum. Rectal bleeding is the most common presenting symptom, occurring in more than half of patients. Other presenting symptoms include prolapsing polyp, melena, pain, iron deficiency anemia, and diarrhea [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1,9,16\" class=\"abstract_t\">1,9,16</a>]. Most patients are symptomatic by age 20 years [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/16\" class=\"abstract_t\">16</a>]. (See <a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-mechanical-small-bowel-obstruction-in-adults\" class=\"medical medical_review\">&quot;Epidemiology, clinical features, and diagnosis of mechanical small bowel obstruction in adults&quot;</a> and <a href=\"topic.htm?path=intussusception-in-children\" class=\"medical medical_review\">&quot;Intussusception in children&quot;</a> and <a href=\"topic.htm?path=protein-losing-gastroenteropathy#H2821906469\" class=\"medical medical_review\">&quot;Protein-losing gastroenteropathy&quot;, section on 'Clinical features'</a>.)</p><p>In juvenile polyposis of infancy, juvenile polyps occur in both the upper and lower gastrointestinal tract (including the small bowel) and polyps develop within the first few years of life. Symptoms include diarrhea, bleeding, and intussusception. Macrocephalus and hypotonia may also occur, and patients often die at an early age [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"H499438540\"><span class=\"h3\">Endoscopic and pathological features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Juvenile polyps are hamartomas that develop from an abnormal collection of tissue elements normally present within the intestinal tract (<a href=\"image.htm?imageKey=GAST%2F72376\" class=\"graphic graphic_picture graphicRef72376 \">picture 1</a>). Differentiation between sporadic juvenile polyps and those occurring in the setting of juvenile polyposis syndrome (JPS) may be challenging [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/5,9,17\" class=\"abstract_t\">5,9,17</a>]. Endoscopically, juvenile polyps vary in size from small sessile nodules to large pedunculated lesions measuring several centimeters. Smaller polyps are often rounded and smooth, while larger polyps may be multilobulated. A small white exudate may also be found [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9\" class=\"abstract_t\">9</a>]. Microscopically, juvenile polyps are characterized by both abundant lamina propria, which may be edematous and contain inflammatory cells, and dilated glands forming mucin-filled cysts. </p><p>While JPS is a hamartomatous polyp syndrome, adenomatous changes are also thought to play a role in the development of malignancy. Adenomatous changes have been demonstrated in up to 50 percent of juvenile polyps in JPS [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1,9\" class=\"abstract_t\">1,9</a>]. </p><p class=\"headingAnchor\" id=\"H3991344836\"><span class=\"h2\">Cancer risk</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with JPS are at increased risk for colorectal cancer. The cumulative risk of colorectal cancer in individuals with JPS is 17 to 22 percent by age 35 years and 68 percent by age 60 years [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/18,19\" class=\"abstract_t\">18,19</a>]. Colorectal cancer in JPS occurs at a younger age as compared with sporadic colorectal cancer (mean age 34 years). Individuals with JPS are also at increased risk for gastric cancer, with an estimated lifetime risk of 20 to 30 percent and a mean age at diagnosis of 58 years (range 21 to 73 years) [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1,9,18\" class=\"abstract_t\">1,9,18</a>].</p><p class=\"headingAnchor\" id=\"H499438624\"><span class=\"h2\">Associated conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>JPS due to <em>SMAD4</em> mutations may also be associated with hereditary hemorrhagic telangiectasia (HHT) [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/12\" class=\"abstract_t\">12</a>]. The most common clinical manifestations of HHT are telangiectasias of the skin and buccal mucosa, epistaxis, and iron deficiency anemia from bleeding. Other conditions associated with JPS include cardiac (eg, mitral valve prolapse), vascular (eg, arterial aneurysms), skeletal, and cranial abnormalities [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H8\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H499438429\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A clinical diagnosis of JPS is based on the presence of at least one of the following criteria and the absence of clinical manifestations of other hamartomatous polyposis syndromes (see <a href=\"#H369224203\" class=\"local\">'Differential diagnosis'</a> below) [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1,9\" class=\"abstract_t\">1,9</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>More than five juvenile polyps in the colorectum</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Multiple juvenile polyps in other parts of the gastrointestinal tract</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Any number of juvenile polyps in a person with a known family history of juvenile polyps</p><p/><p>Individuals who meet clinical criteria for JPS should undergo genetic testing for a germline mutation in the <em>BMPR1A</em> and<em> SMAD4</em> genes. Genetic testing in an individual who meets clinical criteria for JPS serves to confirm the diagnosis of JPS and to counsel at-risk family members. (See <a href=\"#H369224190\" class=\"local\">'Genetics'</a> above.)</p><p class=\"headingAnchor\" id=\"H369224203\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Juvenile polyposis syndrome (JPS) can be differentiated from other disorders that present with multiple hamartomatous gastrointestinal polyps based on the clinical presentation, histologic findings, and genetic testing.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Phosphatase and tensin homolog</strong><strong><em> </em></strong><strong>(</strong><strong><em>PTEN</em></strong><strong>) hamartoma tumor syndrome</strong> &ndash; Hamartomatous polyps of the small intestine can be associated with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome (BRRS). Cowden syndrome and BRRS are associated with germline mutations in <em>PTEN1</em>. BRRS is characterized by macrocephaly, lipomas, vascular abnormalities, and developmental delay. Cowden syndrome has characteristic skin and oral findings including trichilemmomas, acral keratoses, and facial <span class=\"nowrap\">papules/oral</span> papillomas. Pigmented spots in BRRS and Cowden syndrome characteristically occur on the glans penis in males [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/3,9\" class=\"abstract_t\">3,9</a>]. (See <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome#H462459902\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;, section on 'Cowden syndrome'</a> and <a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome#H462460023\" class=\"medical medical_review\">&quot;PTEN hamartoma tumor syndrome, including Cowden syndrome&quot;, section on 'Bannayan-Riley-Ruvalcaba syndrome'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Peutz-Jeghers syndrome </strong>&ndash; Peutz-Jeghers syndrome is an autosomal dominant syndrome characterized by multiple hamartomatous Peutz-Jeghers-type polyps in the gastrointestinal tract, mucocutaneous pigmentation, and an increased risk of gastrointestinal and non-gastrointestinal cancer. Peutz-Jeghers syndrome is associated with germline mutations in the <em>STK11 </em>(<em>LKB1</em>)<em> </em>gene<em> </em>encoding a <span class=\"nowrap\">serine/threonine</span> kinase mapped to chromosome 19p13.3 [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9,20\" class=\"abstract_t\">9,20</a>]. (See <a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Nevoid basal cell carcinoma syndrome</strong> &ndash; Nevoid basal cell carcinoma syndrome is an autosomal dominant condition due to mutations in the <em>PTCH1</em> gene and is characterized by multiple basal cell carcinomas, palmar and plantar pitting, and macrocephaly. Rarely, patients may have multiple gastric hamartomatous polyps [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/21\" class=\"abstract_t\">21</a>]. (See <a href=\"topic.htm?path=nevoid-basal-cell-carcinoma-syndrome\" class=\"medical medical_review\">&quot;Nevoid basal cell carcinoma syndrome&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H21759711\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Guidelines for cancer screening in patients with juvenile polyposis syndrome (JPS) have been proposed by several groups and are largely based on expert opinion and limited observational data [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9,22\" class=\"abstract_t\">9,22</a>]. Our recommendations are largely consistent with the guidelines issued by the American College of Gastroenterology and the National Comprehensive Cancer Network [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9,23\" class=\"abstract_t\">9,23</a>]. </p><p>Individuals with a pathogenic germline mutation in the <em>BMPR1A</em> and <em>SMAD4 </em>genes, and individuals with a clinical diagnosis of JPS who have not undergone genetic testing or who have indeterminate genetic test results, should be screened for manifestations of JPS as discussed below. (See <a href=\"topic.htm?path=genetic-testing#H33\" class=\"medical medical_review\">&quot;Genetic testing&quot;, section on 'Outcomes of testing'</a>.)</p><p class=\"headingAnchor\" id=\"H426435977\"><span class=\"h2\">Routine evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Individuals with JPS should undergo an annual physical examination including a cardiovascular examination [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1\" class=\"abstract_t\">1</a>] with a complete blood count to evaluate for iron deficiency anemia secondary to blood loss. In addition, patients with pathogenic mutations in <em>SMAD4</em> should be evaluated for hereditary hemorrhagic telangiectasia (HHT) [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/24\" class=\"abstract_t\">24</a>]. When a <em>SMAD4</em> mutation is known within a family, genetic testing should be performed within six months of birth due to the risk of HHT [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/23\" class=\"abstract_t\">23</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H15\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia#H2557811534\" class=\"medical medical_review\">&quot;Management of hereditary hemorrhagic telangiectasia&quot;, section on 'Screening (asymptomatic individuals)'</a>.)</p><p class=\"headingAnchor\" id=\"H426436025\"><span class=\"h2\">Cancer screening</span></p><p class=\"headingAnchor\" id=\"H326297453\"><span class=\"h3\">Colorectal</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Screening for colorectal cancer with colonoscopy should be performed every one to three years, beginning at age 12 years or earlier in patients who present with symptoms [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/10\" class=\"abstract_t\">10</a>]. If polyps are found, colonoscopy should be repeated annually; otherwise, colonoscopy intervals can be increased to every one to three years [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H326297467\"><span class=\"h3\">Upper gastrointestinal tract</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We survey the upper gastrointestinal tract with upper endoscopy starting at the age of 12 years. If polyps are detected, upper endoscopy should be repeated annually. In the absence of upper gastrointestinal tract polyps, upper endoscopy can be performed every two to three years [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9\" class=\"abstract_t\">9</a>].</p><p>The small bowel can be evaluated using small bowel enteroscopy (eg, double balloon enteroscopy), wireless capsule endoscopy, or small bowel imaging. However, the timing and intervals for small bowel screening are not well defined. We perform a baseline exam starting in the teenage years and then repeat it periodically based upon findings or symptoms, including anemia or protein-losing enteropathy. </p><p class=\"headingAnchor\" id=\"H426435959\"><span class=\"h2\">Management of gastrointestinal tract polyps</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Gastrointestinal tract polyps can usually be resected endoscopically [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/16\" class=\"abstract_t\">16</a>]. Indications for colectomy and ileorectal anastomosis (IRA) or proctocolectomy and ileal pouch anal anastomosis include polyp-related symptoms (eg, bleeding), neoplasia, or when the polyps cannot be managed endoscopically. The remaining rectum or pouch should be surveyed following colectomy. Approximately half of the patients undergoing IRA will eventually require proctectomy [<a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9\" class=\"abstract_t\">9</a>]. Complete or partial gastrectomy may be necessary for patients with advanced dysplasia, gastric cancer, or massive gastric polypsis that cannot be effectively managed endoscopically. (See <a href=\"#H326297453\" class=\"local\">'Colorectal'</a> above.) </p><p class=\"headingAnchor\" id=\"H2776815814\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hereditary colorectal cancer syndromes&quot;</a>.)</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topics (see <a href=\"topic.htm?path=colon-and-rectal-cancer-screening-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Colon and rectal cancer screening (The Basics)&quot;</a> and <a href=\"topic.htm?path=colonoscopy-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Colonoscopy (The Basics)&quot;</a>)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=colon-and-rectal-cancer-screening-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Colon and rectal cancer screening (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=colonoscopy-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Colonoscopy (Beyond the Basics)&quot;</a> and <a href=\"topic.htm?path=flexible-sigmoidoscopy-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Flexible sigmoidoscopy (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H21762689\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Juvenile polyposis syndrome (JPS) is a rare autosomal dominant syndrome characterized by multiple juvenile-type hamartomatous polyps in the gastrointestinal tract. The incidence of JPS is between 1 in 100,000 to 160,000 individuals. (See <a href=\"#H369224197\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JPS occurs as a result of germline mutations in the <em>SMAD4 </em>(<em>MADH4</em>) and <em>BMPR1A</em> genes. However, approximately 40 percent of JPS patients have no germline mutation. While 75 percent of patients have a family history of juvenile polyposis, approximately 25 percent are de novo mutations. (See <a href=\"#H369224190\" class=\"local\">'Genetics'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Most patients are symptomatic by age 20 years. Rectal bleeding is the most common presenting symptom. Other symptoms include abdominal pain due to obstruction from intussusception, diarrhea due to protein-losing enteropathy, and rectal prolapse of polyps.</p><p/><p class=\"bulletIndent1\">Polyps begin to appear in the first decade of life, and patients can develop between five to hundreds of polyps in their lifetime. Polyps occur predominantly in the colorectum but can occur in the stomach and small bowel. Individuals with JPS are at increased risk for colorectal and gastric cancer. (See <a href=\"#H620604182\" class=\"local\">'Gastrointestinal manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JPS due to <em>SMAD4</em> mutations may also be associated with hereditary hemorrhagic telangiectasia (HHT). The most common clinical manifestations of HHT are telangiectasias of the skin and buccal mucosa, epistaxis, and iron deficiency anemia from bleeding. (See <a href=\"#H499438624\" class=\"local\">'Associated conditions'</a> above and <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H8\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Clinical features'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A clinical diagnosis of JPS is based on the presence of at least one of the following and the absence of clinical manifestations of other hamartomatous polyposis syndromes:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>More than five juvenile polyps in the colorectum</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Multiple juvenile polyps in other parts of the gastrointestinal tract</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any number of juvenile polyps in a person with a known family history of juvenile polyps</p><p/><p class=\"bulletIndent1\">Individuals who meet clinical criteria for JPS should undergo genetic testing for a germline mutation in the <em>BMPR1A</em> and<em> SMAD4</em> genes. (See <a href=\"#H499438429\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>JPS can be differentiated from other disorders that present with multiple hamartomatous gastrointestinal polyps based on the clinical presentation, histologic findings, and genetic testing. (See <a href=\"#H369224203\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Our approach to the management of patients with JPS is as follows:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Annual physical examination including a cardiovascular examination with a complete blood count to evaluate for iron deficiency anemia. Evaluation for HHT in patients with pathogenic mutations in <em>SMAD4</em>. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome#H15\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)&quot;, section on 'Diagnosis'</a> and <a href=\"#H426435977\" class=\"local\">'Routine evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Colonoscopy and esophagogastroduodenoscopy starting at the age of 12 years, repeated annually if polyps are demonstrated or every two to three years in the absence of polyps. Additional evaluation of small bowel based on the polyp burden and in patients with iron deficiency anemia or abdominal pain. (See <a href=\"#H426436025\" class=\"local\">'Cancer screening'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gastrointestinal tract polyps in JPS can usually be resected endoscopically. Indications for surgery include polyp-related symptoms, neoplasia, or when the polyps cannot be managed endoscopically. (See <a href=\"#H426435959\" class=\"local\">'Management of gastrointestinal tract polyps'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H92670550\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Peter Bonis, MD, Dennis Ahnen, MD, and Lisen Axell, MS, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/1\" class=\"nounderline abstract_t\">Latchford AR, Neale K, Phillips RK, Clark SK. Juvenile polyposis syndrome: a study of genotype, phenotype, and long-term outcome. Dis Colon Rectum 2012; 55:1038.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/2\" class=\"nounderline abstract_t\">MCCOLL I, BUSXEY HJ, VEALE AM, MORSON BC. JUVENILE POLYPOSIS COLI. Proc R Soc Med 1964; 57:896.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/3\" class=\"nounderline abstract_t\">Zbuk KM, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 2007; 4:492.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/4\" class=\"nounderline abstract_t\">Harned RK, Buck JL, Sobin LH. The hamartomatous polyposis syndromes: clinical and radiologic features. AJR Am J Roentgenol 1995; 164:565.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/5\" class=\"nounderline abstract_t\">Chow E, Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 2005; 20:1634.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/6\" class=\"nounderline abstract_t\">Howe JR, Roth S, Ringold JC, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998; 280:1086.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/7\" class=\"nounderline abstract_t\">Fogt F, Brown CA, Badizadegan K, et al. Low prevalence of loss of heterozygosity and SMAD4 mutations in sporadic and familial juvenile polyposis syndrome-associated juvenile polyps. Am J Gastroenterol 2004; 99:2025.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/8\" class=\"nounderline abstract_t\">Burger B, Uhlhaas S, Mangold E, et al. Novel de novo mutation of MADH4/SMAD4 in a patient with juvenile polyposis. Am J Med Genet 2002; 110:289.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/9\" class=\"nounderline abstract_t\">Syngal S, Brand RE, Church JM, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110:223.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/10\" class=\"nounderline abstract_t\">Howe JR, Bair JL, Sayed MG, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001; 28:184.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/11\" class=\"nounderline abstract_t\">Sayed MG, Ahmed AF, Ringold JR, et al. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002; 9:901.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/12\" class=\"nounderline abstract_t\">Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363:852.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/13\" class=\"nounderline abstract_t\">O'Malley M, LaGuardia L, Kalady MF, et al. The prevalence of hereditary hemorrhagic telangiectasia in juvenile polyposis syndrome. Dis Colon Rectum 2012; 55:886.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/14\" class=\"nounderline abstract_t\">Howe JR, Haidle JL, Lal G, et al. ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 2007; 71:91.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/15\" class=\"nounderline abstract_t\">Sweet K, Willis J, Zhou XP, et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294:2465.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/16\" class=\"nounderline abstract_t\">Grotsky HW, Rickert RR, Smith WD, Newsome JF. Familial juvenile polyposis coli. A clinical and pathologic study of a large kindred. Gastroenterology 1982; 82:494.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/17\" class=\"nounderline abstract_t\">Brosens LA, Langeveld D, van Hattem WA, et al. Juvenile polyposis syndrome. World J Gastroenterol 2011; 17:4839.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/18\" class=\"nounderline abstract_t\">Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol 2005; 100:476.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/19\" class=\"nounderline abstract_t\">Brosens LA, van Hattem A, Hylind LM, et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007; 56:965.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/20\" class=\"nounderline abstract_t\">Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/21\" class=\"nounderline abstract_t\">Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis 2008; 3:32.</a></li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/22\" class=\"nounderline abstract_t\">Dunlop MG, British Society for Gastroenterology, Association of Coloproctology for Great Britain and Ireland. Guidance on gastrointestinal surveillance for hereditary non-polyposis colorectal cancer, familial adenomatous polypolis, juvenile polyposis, and Peutz-Jeghers syndrome. Gut 2002; 51 Suppl 5:V21.</a></li><li class=\"breakAll\">National Comprehensive Cancer Network Clinical Practice Guidlines in Oncology. Genetic/Familial High Risk Assessment: Colorectal. http://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf (Accessed on November 13, 2015).</li><li><a href=\"https://www.uptodate.com/contents/juvenile-polyposis-syndrome/abstract/24\" class=\"nounderline abstract_t\">Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91:66.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15805 Version 15.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H21762689\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H620603917\" id=\"outline-link-H620603917\">INTRODUCTION</a></li><li><a href=\"#H369224197\" id=\"outline-link-H369224197\">EPIDEMIOLOGY</a></li><li><a href=\"#H369224190\" id=\"outline-link-H369224190\">GENETICS</a></li><li><a href=\"#H369224170\" id=\"outline-link-H369224170\">CLINICAL FEATURES</a><ul><li><a href=\"#H620604182\" id=\"outline-link-H620604182\">Gastrointestinal manifestations</a><ul><li><a href=\"#H499438540\" id=\"outline-link-H499438540\">- Endoscopic and pathological features</a></li></ul></li><li><a href=\"#H3991344836\" id=\"outline-link-H3991344836\">Cancer risk</a></li><li><a href=\"#H499438624\" id=\"outline-link-H499438624\">Associated conditions</a></li></ul></li><li><a href=\"#H499438429\" id=\"outline-link-H499438429\">DIAGNOSIS</a></li><li><a href=\"#H369224203\" id=\"outline-link-H369224203\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H21759711\" id=\"outline-link-H21759711\">MANAGEMENT</a><ul><li><a href=\"#H426435977\" id=\"outline-link-H426435977\">Routine evaluation</a></li><li><a href=\"#H426436025\" id=\"outline-link-H426436025\">Cancer screening</a><ul><li><a href=\"#H326297453\" id=\"outline-link-H326297453\">- Colorectal</a></li><li><a href=\"#H326297467\" id=\"outline-link-H326297467\">- Upper gastrointestinal tract</a></li></ul></li><li><a href=\"#H426435959\" id=\"outline-link-H426435959\">Management of gastrointestinal tract polyps</a></li></ul></li><li><a href=\"#H2776815814\" id=\"outline-link-H2776815814\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H92573158\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H21762689\" id=\"outline-link-H21762689\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H92670550\" id=\"outline-link-H92670550\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/15805|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/72376\" class=\"graphic graphic_picture\">- Juvenile colonic polyp Light</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-familial-adenomatous-polyposis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of familial adenomatous polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-hereditary-hemorrhagic-telangiectasia-osler-weber-rendu-syndrome\" class=\"medical medical_review\">Clinical manifestations and diagnosis of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-features-and-diagnosis-of-mechanical-small-bowel-obstruction-in-adults\" class=\"medical medical_review\">Epidemiology, clinical features, and diagnosis of mechanical small bowel obstruction in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=genetic-testing\" class=\"medical medical_review\">Genetic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=intussusception-in-children\" class=\"medical medical_review\">Intussusception in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=mutyh-associated-polyposis\" class=\"medical medical_review\">MUTYH-associated polyposis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=management-of-hereditary-hemorrhagic-telangiectasia\" class=\"medical medical_review\">Management of hereditary hemorrhagic telangiectasia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nevoid-basal-cell-carcinoma-syndrome\" class=\"medical medical_review\">Nevoid basal cell carcinoma syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pten-hamartoma-tumor-syndrome-including-cowden-syndrome\" class=\"medical medical_review\">PTEN hamartoma tumor syndrome, including Cowden syndrome</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=colon-and-rectal-cancer-screening-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Colon and rectal cancer screening (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=colon-and-rectal-cancer-screening-the-basics\" class=\"medical medical_basics\">Patient education: Colon and rectal cancer screening (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=colonoscopy-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Colonoscopy (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=colonoscopy-the-basics\" class=\"medical medical_basics\">Patient education: Colonoscopy (The Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=flexible-sigmoidoscopy-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Flexible sigmoidoscopy (Beyond the Basics)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=peutz-jeghers-syndrome-epidemiology-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Peutz-Jeghers syndrome: Epidemiology, clinical manifestations, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=protein-losing-gastroenteropathy\" class=\"medical medical_review\">Protein-losing gastroenteropathy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hereditary-colorectal-cancer-syndromes\" class=\"medical medical_society_guidelines\">Society guideline links: Hereditary colorectal cancer syndromes</a></li></ul></div></div>","javascript":null}